Medifast reported a $17.5 million Q3 2026 loss driven by restructuring, while coach productivity rose 54% and management ...

A new study suggests that women using menopause hormone therapy alongside GLP-1 medications like Wegovy may experience greater weight loss.

Medifast (NYSE:MED) reported third-quarter 2026 revenue of $72 million, down 19.4% from a year earlier, as the company continued to face a sharp decline in its active earning coach base. Management sa ...

Medifast, Inc. provided earnings guidance for the fourth quarter and full year of 2026. For the quarter, the company expects fourth quarter 2026 revenue to be in the range of $55 million to ...

Medifast (NYSE: MED), the metabolic health and wellness company known for its science-backed comprehensive metabolic health system, Trilivy™, today reported results for the third quarter ended ...